Stepwise development of a cancer care delivery research study to evaluate the prevalence of virus infections in cancer patients

Future Oncology

Volumn 12, Issue 10, 2016, Pages 1219-1231

  Unger, Joseph M ^a   Hershman, Dawn L ^b   Arnold, Kathryn B ^a   Loomba, Rohit ^c   Chugh, Rashmi ^d   Hwang, Jessica P ^e   O'rourke, Mark A ^f   Bhadkamkar, Nishin A ^e   Wang, Lili X ^g,h   Siegel, Abby B ^b   Cooley, Timothy P ⁱ   Berenberg, Jeffrey L ^j   Bridges, Benjamin B ^k,l   Ramsey, Scott D ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f GREENVILLE HOSPITAL SYSTEM   (United States)

^g Bay Area Institute NCORP Oakland   (United States)

^h Landstuhl Regional Medical Center   (United States)

ⁱ BOSTON MEDICAL CENTER   (United States)

^j UNIVERSITY OF HAWAII   (United States)

^k Pacific Cancer Research Consortium NCORP   (United States)

^l St Luke's Mountain States Tumor Institute   (United States)

more..

Author keywords

cancer care delivery research; screening; viral infections in cancer patients

Indexed keywords

ADULT; ARTICLE; CANCER CENTER; CANCER PATIENT; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL RESEARCH; COMMUNITY CARE; FEMALE; HEALTH CARE DELIVERY; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; SCREENING; STUDY DESIGN; VIRUS DIAGNOSIS; VIRUS INFECTION; MASS SCREENING; NEOPLASM; PROCEDURES; VIROLOGY; VIRUS DISEASES;

DELIVERY OF HEALTH CARE; HUMANS; MASS SCREENING; NEOPLASMS; PREVALENCE; RESEARCH DESIGN; VIRUS DISEASES;

EID: 84965097589     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon-2015-0076     Document Type: Article

References (21)

1. National Cancer Institute: NCI Community Oncology Research Program (NCORP) Research Bases (UM1) http://grants.nih.gov
2. National Cancer Institute, US Department of Health and Human Services, National Institutes of Health. Implementing a National Cancer Clinical Trials System for the 21st Century: Workshop #2. February 2013. www.iom.edu
3. Ramsey SD, Sullivan SD, Reed SD., et al. Oncology comparative effectiveness research: a multistakeholder perspective on principles for conduct and reporting. Oncologist 18(6), 760-767 (2013).
4. Centers for Disease Control. HIV Among Older Americans. www.cdc.gov
5. Li J, Thompson TD, Tai E, Zhao G, Oster AM. Testing for human immunodeficiency virus among cancer survivors under age 65 in the United States. Prev. Chronic Dis. 11, 1-14 (2014).
6. Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS. Underrepresentation of patients 65 years of age or older in cancer-Treatment trials. N. Engl. J. Med. 341(27), 2061-2067 (1999).
7. Centers for Disease Control. Hepatitis B-General Fact Sheet. www.cdc.gov
8. Moyer VA. U.S. Preventive Services Task Force. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 159(5), 349-357 (2013).
9. Hoofnagle JH. Reactivation of hepatitis B. Hepatology 49(5 Suppl.), S156-S165 (2009).
10. Ifuku H, Kusumoto S, Tanaka Y., et al. Fatal reactivation of hepatitis B virus infection in a patient with adult T-cell leukemia-lymphoma receiving the anti-CC chemokine receptor 4 antibody mogamulizumab. Hepatol. Res. 45(13), 1363-1367 (2015).
11. Sera T, Hiasa Y, Michitaka K., et al. Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab. Intern. Med. 45(11), 721-724 (2006).
12. Mahale P, Kontoyiannis DP, Chemaly RF., et al. Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients. J. Hepatol. 57(6), 1177-1185 (2012).
13. Moyer VA. U.S. Preventive Services Task Force. Screening for HIV: U.S. Preventive Services Task Force Recommendation Statement. Ann. Intern. Med. 159(1), 51-60 (2013).
14. Branson BM, Handsfield HH, Lampe MA., et al. Centers for Disease Control and Prevention (CDC). Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm. Rep. 55(RR-14), 1-17 (2006).
15. Qaseem A, Snow V, Shekelle P, Hopkins R Jr, Owens DK. Screening for HIV in health care settings: a guidance statement from the American College of Physicians and HIV Medicine Association. Ann. Intern. Med. 150(2), 125-131 (2009).
16. Weinbaum CM, Williams I, Mast EE., et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm. Rep. 57(RR-8), 1-20 (2008).
17. Hwang JP, Somerfield MR, Alston-Johnson DE., et al. Hepatitis B virus screening for patients with cancer before therapy: American Society of Clinical Oncology provisional clinical opinion update. J. Clin. Oncol. 33(19), 2212-2220 (2015).
18. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm. Rep. 47(No. RR-19), 1-39 (1998).
19. Smith BD, Morgan RL, Beckett GA., et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm. Rep. 61(RR-4), 1-32 (2012).
20. Green S, Benedetti J, Crowley J. Clinical Trials in Oncology (2nd Edition). CRC Press, FL, USA (2003).
21. Ramsey SD, Barlow WE, Gonzalez-Angulo AM., et al. Integrating comparative effectiveness design elements and endpoints into a phase III, randomized clinical trial (SWOG S1007) evaluating OncotypeDX-guided management for women with breast cancer involving lymph nodes. Contemp. Clin. Trials 34(1), 1-9 (2013).